21st Aug 2015 07:00
Venn Life Sciences Holdings Plc
("Venn" the "Company" or the "Group")
Notice of Results
Investor Results Presentation
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, will be reporting its interim results for the six months ended 30 June 2015 on Tuesday 22 September 2015.
Analyst presentation
Tony Richardson, Chief Executive Officer and Jonathan Hartshorn, Chief Financial Officer will be hosting an analyst briefing on the day of results, Tuesday 22 September 2015, at 9.30am at Walbrook PR, 4 Lombard Street, London, EC3V 9HD.
Investor results presentation
A briefing for all investors will take place on Tuesday 22 September 2015 at Rocket, 6 Adams Court, Old Broad Street, London, EC4N 1DX from 5.00pm for a 5.15pm start, and will be followed by drinks and canapés.
If you would like to register to attend either presentation, or require further information, please contact Lianne Cawthorne on +44(0)20 7933 8788 or email [email protected]
For further information:
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com |
Tony Richardson, Chief Executive Officer Jonathan Hartshorn, Chief Financial Officer | Tel: +353 154 99 341 Tel: +353 153 93 269 |
Orla McGuinness, Marketing Manager | Tel: +33 (0)1 30 82 67 07 |
|
|
Zeus Capital (Nominated Adviser and Broker) |
|
Ross Andrews/Andrew Jones (Corporate Finance) | Tel: 0161 831 1512 |
Alex Davies (Institutional Sales) | Tel: 020 7533 7727 |
|
|
Walbrook PR Ltd | Tel: 020 7933 8787 or [email protected] |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
About Venn Life Sciences Limited:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
Related Shares:
ORPH.L